Last mentioned: Mar 18, 2026
Across the most recent 3 stories covering Central Drugs Standard Control Organisation (CDSCO) — 67% positive, 33% negative sentiment, averaging 6.7/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Target Milestone
Goal to reach $50 billion market size and 10-12% global market share.
Contempt Notice Issued
Justice Sachin Datta issues formal notice to CDSCO seeking an explanation for the delay.
Rollout of Production Linked Incentive schemes for high-end medical equipment.
Chintan Shivir
Department of Commerce holds strategic brainstorming to boost exports.
Contempt Petition Filed
Petitioners move court alleging CDSCO failed to meet the review deadline.
Initial Court Order
Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.
Policy Launch
National Medical Device Policy 2023 is officially notified.
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
The Indian Department of Commerce has convened a 'Chintan Shivir' to overhaul the nation's medical device export framework. This strategic brainstorming session aims to address regulatory hurdles and incentivize domestic manufacturing to position India as a global med-tech hub.
Source: oklahomacitysun.com · russiaherald.com
This page surfaces every story mentioning Central Drugs Standard Control Organisation (CDSCO) across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Central Drugs Standard Control Organisation (CDSCO) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |